Retension Pharmaceuticals, Inc. (RTSN) stock
RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)
Close on Nov 18, 2026Market cap $11.22MP/E –Yield –
Retension Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Retension Pharmaceuticals
Retension Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?